Cutera (CUTR) Set to Announce Quarterly Earnings on Thursday

Cutera (NASDAQ:CUTR) is set to announce its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($1.09) per share for the quarter. Cutera has set its FY 2024 guidance at EPS.Investors that wish to listen to the company’s conference call can do so using this link.

Cutera (NASDAQ:CUTR) last posted its quarterly earnings data on Thursday, March 21st. The medical device company reported ($2.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($1.07). The company had revenue of $49.54 million for the quarter, compared to analyst estimates of $49.10 million. On average, analysts expect Cutera to post $-6 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cutera Stock Performance

NASDAQ CUTR opened at $2.75 on Wednesday. The company has a market capitalization of $54.85 million, a PE ratio of -0.37 and a beta of 1.43. The company has a 50-day simple moving average of $1.98 and a 200 day simple moving average of $2.52. Cutera has a 52-week low of $1.28 and a 52-week high of $21.41.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Stephens reiterated an “overweight” rating and issued a $10.00 target price on shares of Cutera in a research note on Friday, March 22nd. William Blair upgraded shares of Cutera from an “underperform” rating to a “market perform” rating in a research note on Friday, March 22nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $14.75.

About Cutera

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for deep dermal remodeling; truFlex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; and excel V+, a vascular and benign pigmented lesion treatment platform.